ĐÁNH GIÁ HIỆU QUẢ MỘT SỐ THUỐC ĐIỀU TRỊ ĐÁI THÁO ĐƯỜNG TÝP 2 TẠI TRUNG TÂM Y TẾ KHU VỰC GÒ CÔNG TÂY

Abstract

Background: The management of diabetes mellitus at the primary healthcare level is one of the strategies that bring significant benefits and treatment effectiveness for patients. Objective: To evaluate the effectiveness and cost-effectiveness of the combined regimen of metformin and glimepiride compared to metformin monotherapy in the treatment of type 2 diabetes mellitus at Go Cong Tay Regional Health Center. Subjects and Methods: A cross-sectional descriptive study was conducted on 62 patients diagnosed with type 2 diabetes mellitus at Go Cong Tay Regional Health Center, divided into two groups: the combination group, consisting of 31 patients treated with a regimen of metformin 1000 mg combined with glimepiride 2 mg, and the monotherapy group, consisting of 31 patients treated with metformin 1000 mg alone. Results: The mean plasma glucose level after three treatment cycles in the combination group (metformin plus glimepiride) was 7.80 ± 2.15 mmol/L, which was lower than that in the metformin monotherapy group (8.23 ± 1.95 mmol/L). The mean reduction in plasma glucose after three treatment cycles in the combination group was 0.69 ± 1.01 mmol/L, higher than that in the monotherapy group (0.55 ± 0.49 mmol/L). The combination regimen was dominant in terms of cost-effectiveness compared with the monotherapy regimen, with an ICER value of –126,275 VND per mmol/L of glucose reduction. Conclusion: The combination of metformin and glimepiride was more effective and cost-effective than metformin monotherapy in the treatment of type 2 diabetes mellitus. This finding suggests that the combined regimen may optimize the allocation of healthcare resources and provide additional real-world evidence for health technology assessment.